Research hub · 8 articles
SARMs & Receptor Selectivity
Selective androgen receptor modulators are small synthetic molecules that bind the androgen receptor without a steroidal scaffold. That single structural difference is the whole point of the class and also the source of most of its analytical difficulty: several of these compounds are chiral, so a certificate that does not state enantiomeric composition is describing a mixture, not a standard.
The literature on this class is thinner than its commercial presence suggests, so these pages spend their space on what is measurable. Eight articles deal with the class directly: an overview of the series and its regulatory record; compound pages for Ostarine, RAD-140, LGD-4033 and Andarine, each with identity data and its own documented off-target story; a page on SR-9009, which is shelved with SARMs commercially but binds REV-ERB rather than the androgen receptor; a head-to-head comparing Ostarine against RAD-140; and an analytical piece on how these materials are actually verified — retention matching, mass confirmation, chiral composition and the adulteration patterns that make label-based identity worthless. Nothing in this cluster should be read as an efficacy claim: these are reference materials for laboratory work.
If the class is new to you, read the overview first and the compound pages second. The overview explains why receptor-selectivity claims are harder to substantiate than the marketing suggests, and the compound pages show what documentation a reference standard should carry before it is used to standardise anything — identity, purity by peak area, and the chiral composition that a bare percentage hides.
Articles in this hub
SARMs for Research: What the Class Really Is
A level-headed guide to selective androgen receptor modulators as research compounds — scaffold families, why 'selective' was the point, the mislabeling scandal that defines the market, and what legitimate SARM research looks like.
10 Sept 2026
Ostarine (MK-2866): The Prototype SARM, Revisited
Enobosarm is the most studied SARM in the catalog: phase II human data, a single stereocentre that decides what the standard actually is, and a documentation trail worth reading before any assay.
16 Nov 2026
Ostarine vs RAD-140: Preclinical Evidence Compared
The two most-searched SARMs compared on the only axes that hold up: receptor pharmacology, published human trial data (one has them, one doesn't), and what the enobosarm program's end tells researchers.
10 Sept 2026
RAD-140 (Testolone): The Preclinical SARM
Testolone is the highest-affinity SARM in most published receptor panels — and has zero completed human trials. What preclinical science establishes, what it cannot, and how to spec it analytically.
10 Sept 2026
LGD-4033 (Ligandrol): The Human-Trial SARM
Ligandrol is one of few SARMs with published human-phase data — and that data is precisely what makes it a documentation-first research compound. Chemistry, trial record, and analytical specs.
10 Sept 2026
Andarine (S-4): The First-Generation SARM Standard
Andarine is the molecule that defined the SARM template — and the one whose retinal off-target findings defined the limits of the selectivity claim. Chemistry, detection and handling.
16 Nov 2026
SR-9009: A REV-ERB Agonist, Not a SARM
SR-9009 is shelved with SARMs by vendors and binds no androgen receptor at all. What it actually targets, why its oral exposure is poor, and what the published case report records.
16 Nov 2026
Testing SARMs: Purity, Adulteration and Assay Design
Chemical purity is not receptor activity, and a label is not an identity. How SARM reference materials are actually verified — methods, common adulterants and the questions to ask.
16 Nov 2026
Related categories
Related tools
More hubs and compound references in the research journal; analytical documentation on the quality page; or request a quote.